By Gregg Goldfarb ( February 21, 2025, 5:12 PM EST) -- The rapid ascent of glucagon-like peptide-1 receptor agonists, or GLP-1 RAs — such as Novo Nordisk's Ozempic and Wegovy, and Eli Lilly & Co.'s Mounjaro and Zepbound — has revolutionized diabetes management and weight loss....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.